

22-11-2016

Physical multimorbidity and psychosis: comprehensive cross sectional analysis including 242,952 people across 48 low- and middle-income countries

Brendon Stubbs
King's College London

Ai Koyanagi
Universitat de Barcelona

Nicola Veronese
University of Padova

Davy Vancampfort
KU Leuven

Marco Solmi
University of Padova

See next page for additional authors

Citation

Stubbs B, Koyanagi A, Veronese N, Vancampfort D, Solmi M, Gaughran F, Carvalho AF, Lally J, Mitchell AJ, Mugisha J, Correll CU. Physical multimorbidity and psychosis: comprehensive cross sectional analysis including 242,952 people across 48 low- and middle-income countries. *BMC Medicine*. 2016;14:189.

This Article is brought to you for free and open access by the Department of Psychiatry at e-publications@RCSI. It has been accepted for inclusion in Psychiatry Articles by an authorized administrator of e-publications@RCSI. For more information, please contact epubs@rcsi.ie.

Authors

Brendon Stubbs, Ai Koyanagi, Nicola Veronese, Davy Vancampfort, Marco Solmi, Fiona Gaughran, Andre Carvalho, John Lally, Alex J. Mitchell, James Mugisha, and Christoph U. Correll

— Use Licence —



This work is licensed under a [Creative Commons Attribution-Noncommercial-Share Alike 4.0 License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

RESEARCH ARTICLE

Open Access



Physical multimorbidity and psychosis: comprehensive cross sectional analysis including 242,952 people across 48 low- and middle-income countries

Brendon Stubbs^{1,2*}, Ai Koyanagi^{3,4}, Nicola Veronese^{5,6}, Davy Vancampfort^{7,8}, Marco Solmi^{6,9,10}, Fiona Gaughran¹¹, André F. Carvalho¹², John Lally^{11,13}, Alex J. Mitchell¹⁴, James Mugisha^{15,16} and Christoph U. Correll^{17,18}

Abstract

Background: In people with psychosis, physical comorbidities, including cardiovascular and metabolic diseases, are highly prevalent and leading contributors to the premature mortality encountered. However, little is known about physical health multimorbidity in this population or in people with subclinical psychosis and in low- and middle-income countries (LMICs). This study explores physical health multimorbidity patterns among people with psychosis or subclinical psychosis.

Methods: Overall, data from 242,952 individuals from 48 LMICs, recruited via the World Health Survey, were included in this cross-sectional study. Participants were subdivided into those (1) with a lifetime diagnosis of psychosis (“psychosis”); (2) with more than one psychotic symptom in the past 12 months, but no lifetime diagnosis of psychosis (“subclinical psychosis”); and (3) without psychotic symptoms in the past 12 months or a lifetime diagnosis of psychosis (“controls”). Nine operationalized somatic disorders were examined: arthritis, angina pectoris, asthma, diabetes, chronic back pain, visual impairment, hearing problems, edentulism, and tuberculosis. The association between psychosis and multimorbidity was assessed by multivariable logistic regression analysis.

Results: The prevalence of multimorbidity (i.e., two or more physical health conditions) was: controls = 11.4% (95% CI, 11.0–11.8%); subclinical psychosis = 21.8% (95% CI, 20.6–23.0%), and psychosis = 36.0% (95% CI, 32.1–40.2%) ($P < 0.0001$). After adjustment for age, sex, education, country-wise wealth, and country, subclinical psychosis and psychosis were associated with 2.20 (95% CI, 2.02–2.39) and 4.05 (95% CI, 3.25–5.04) times higher odds for multimorbidity. Moreover, multimorbidity was increased in subclinical and established psychosis in all age ranges (18–44, 45–64, ≥ 65 years). However, multimorbidity was most evident in younger age groups, with people aged 18–44 years with psychosis at greatest odds of physical health multimorbidity (OR = 4.68; 95% CI, 3.46–6.32).

(Continued on next page)

* Correspondence: brendon.stubbs@kcl.ac.uk

¹Physiotherapy Department, South London and Maudsley NHS Foundation Trust, Denmark Hill, London SE5 8AZ, UK

²Health Service and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, De Crespigny Park, London, Box SE5 8AF, UK

Full list of author information is available at the end of the article



(Continued from previous page)

Conclusions: This large multinational study demonstrates that physical health multimorbidity is increased across the psychosis-spectrum. Most notably, the association between multimorbidity and psychosis was stronger among younger adults, thus adding further impetus to the calls for the early intervention efforts to prevent the burden of physical health comorbidity at later stages. Urgent public health interventions are necessary not only for those with a psychosis diagnosis, but also for subclinical psychosis to address this considerable public health problem.

Keywords: Psychosis, Physical health, Multimorbidity, Psychotic experiences, Metabolism

Background

There is now established evidence that people with psychosis experience a premature mortality gap of up to 15 years before members of the general population [1, 2]. The overwhelming majority of premature mortality cases is due to physical health comorbidities, such as cardiovascular, metabolic, and respiratory diseases [3]. Recent studies have demonstrated that people with psychosis are at greatly increased risk of cardiovascular disease [4], metabolic syndrome [5], diabetes [6], and respiratory disease [7], and that these risks are especially increased compared to similarly aged healthy populations [8, 9]. In addition, people with psychosis may be more likely to experience other physical health conditions, such as arthritis, chronic back pain [10], or edentulism, which may not increase the risk of premature mortality, but which can negatively impact quality of life, for example, via pain or social stigmatization [11].

Despite the knowledge of the heightened risk of various physical comorbidities, very little is known about multimorbidity (i.e., two or more physical health comorbidities) in people with psychosis. However, multimorbidity is an important risk concept, as it has been associated with functional decline [12], worse quality of life [13], increased risk of premature mortality [14, 15], and increased health-care costs [16]. In the largest study to date, people with schizophrenia in Scotland ($n = 9677$) were significantly more likely to have two physical health comorbidities (OR = 1.37, 95% CI, 1.29–1.44) and three or more physical health comorbidities (OR = 1.19, 95% CI, 1.12–1.27) than general population controls [17]. Whilst helpful, the focus in this study was on primary care records limited to one country, and therefore the results are not easily generalizable. Moreover, there is increasing recognition that psychosis lies on a continuum, and that those with psychotic symptoms without a full diagnosis (subclinical psychosis) also experience an increased risk of various physical comorbidities [18–20] and mortality [21]. To our knowledge, no study has investigated multimorbidity in those with subclinical psychosis. Understanding multimorbidity patterns can help identify higher risk subgroups, which would preferentially benefit from tailored preventative and therapeutic strategies [22, 23].

Furthermore, data regarding multimorbidity in low- and middle-income countries (LMICs) are scarce and there is a lack of data on multimorbidity among those with psychosis in this setting. This lacking literature represents an important research gap since increasing trends of multimorbidity in LMICs will have considerable financial implications over the next few decades [24]. In addition, multimorbidity patterns in people with psychosis in the context of LMICs may differ from those in high-income countries. For example, the risk for cardio-metabolic diseases may differ due to limited availability of second-generation antipsychotics, many of which are known to especially increase the risk for metabolic abnormalities [6, 7]. When antipsychotics are available in LMICs, first-generation antipsychotics are commonly prescribed [25]. Particularly high-potency first generation-antipsychotics appear to have a lower cardiometabolic risk profile than most of the second-generation antipsychotics used in high-income countries [26–28]. In addition, although smoking is known to be a major risk factor for cardiovascular diseases for patients with schizophrenia in developed countries, the rate of smoking among those with schizophrenia is not elevated compared to the general population in some LMICs, where smoking rates have remained high in the general population [29].

Given these aforementioned gaps in the literature, we set out to assess the prevalence of physical comorbidity and multimorbidity patterns in adults with psychosis and sub-clinical psychosis across 48 LMICs. We hypothesized that a clinically significant proportion of people would be affected by physical multimorbidity and that there would be a dose–response relationship with psychosis, such that adults with subclinical psychosis would be in between the general population and those with established psychotic disorders.

Methods

The World Health Survey (WHS) was a cross-sectional study undertaken in 2002–2004 in 70 countries worldwide. The aim of the study was to provide global comparable population data on health and well-being among adults. Details of the survey have been provided on the World Health Organization (WHO) website (<http://www.who.int/>)

healthinfo/survey/en/) and in previous publications [30, 31]. Briefly, single-stage random sampling and stratified multi-stage random cluster sampling were conducted in 10 and 60 countries, respectively. Stratification was conducted by sex, age, and residential area (rural/urban). Enumeration areas and households were also used as stratification units in the majority of countries. Persons aged 18 years or older with a valid home address were eligible to participate. Each member of the household had equal probability of being selected with the use of Kish tables. The data were collected in all countries using the same standardized questionnaire with some countries using a shorter version (mainly high-income countries). Since the questions on psychosis were not included in the shorter version, this meant that information on psychosis was absent from the vast majority of high-income countries. The questionnaire was translated into multiple languages and was back- and forward-translated using a standard WHO protocol, and checked by linguists to ensure comparability. Data collection was conducted either by face-to-face interviews or via telephone (Luxembourg and Israel) by trained interviewers who had at least a high school-level education. The interviewers attended a week-long course and conducted practice field interviews prior to the actual survey. The individual response rate across all countries was 98.5% [32]. Ethical approval to conduct this survey was obtained from ethical boards at each study site. Sampling weights were generated to adjust for non-response and the population distribution reported by the United Nations Statistical Division. Informed consent was obtained from all participants.

The current study used data from 69 countries that have been made publically available. The data were nationally representative in all countries with the exception of China, Comoros, the Republic of Congo, Ivory Coast, India, and Russia. Countries without any sampling information (10 countries – Austria, Belgium, Denmark, Germany, Greece, Guatemala, Italy, Netherlands, Slovenia, and UK) were not included in the analysis. Of the remaining 59 countries, nine (Finland, France, Ireland, Israel, Luxembourg, Norway, Portugal, Sweden, and Turkey) were subsequently excluded due to missing information on psychosis. Furthermore, the two remaining high-income countries (Spain and United Arab Emirates) were also excluded. Thus, the final sample included 48 countries (21 low-income and 27 middle-income countries based on the World Bank classification in 2003).

Physical health conditions

A total of nine physical conditions were assessed, representing all physical conditions available in the WHS. Arthritis, asthma, and diabetes mellitus were based on

self-reported lifetime diagnosis. For angina pectoris, in addition to a self-reported diagnosis, a symptom-based diagnosis based on the Rose questionnaire was also used [33]. Chronic back pain was defined as having had back pain (including disc problems) everyday during the last 30 days. Visual impairment was defined as having extreme difficulty in seeing and recognizing a person that the participant knows across the road (i.e., from a distance about 20 meters) [34]. A validity study showed that this response likely corresponds to WHO definitions of visual impairment (20/60 or 0.48 log-MAR) [34]. The participant was considered to have hearing problems if the interviewer observed this condition at the end of the survey. Edentulism was assessed by the question “Have you lost all your natural teeth?” Those who responded affirmatively were considered to have edentulism. Finally, a tuberculosis diagnosis was based on past 12-month symptoms and was defined as (1) having had a cough that lasted for three weeks or longer; and (2) having had blood in phlegm or coughed up blood [35]. We calculated the total number of these conditions while allowing for one missing variable in order to retain a larger sample size. Multimorbidity was defined as having at least two conditions, in line with previously used definitions [24].

Psychosis diagnosis and psychotic symptoms

Participants were asked whether they had ever received a diagnosis of schizophrenia or psychosis. All participants, regardless of a psychosis diagnosis, were asked questions on positive psychotic symptoms which came from the WHO Composite International Diagnostic Interview (CIDI) 3.0 [36]. This psychosis module has been reported to be highly consistent with clinician ratings [37]. The hallucinations question excluded conditions associated with sleep-related states or substance use. Specifically, respondents were asked the following questions with answer options ‘yes’ or ‘no’: During the last 12 months, have you experienced (1) ‘A feeling something strange and unexplainable was going on that other people would find hard to believe?’ (delusional mood); (2) ‘A feeling that people were too interested in you or there was a plot to harm you?’ (delusions of reference and persecution); (3) ‘A feeling that your thoughts were being directly interfered or controlled by another person, or your mind was being taken over by strange forces?’ (delusions of control); (4) ‘An experience of seeing visions or hearing voices that others could not see or hear when you were not half asleep, dreaming or under the influence of alcohol or drugs?’ (hallucinations).

Individuals who endorsed at least one of the four abovementioned psychotic symptoms were considered to have psychotic symptoms. Based on information on

psychosis diagnosis and psychotic symptoms, a three-category psychosis variable was constructed: (1) no psychosis diagnosis and no psychotic symptoms (control group); (2) at least one psychotic symptom but no psychosis diagnosis (subclinical psychosis group); and (3) psychosis diagnosis (psychosis group).

Other variables

Information was also examined on age, sex, country-wise wealth, and education. Principal component analysis based on 15–20 assets was conducted to establish country-wise wealth quintiles. Specifically, based on information on whether the participant owns items, such as a bicycle, refrigerator, washing machine, computer, etc., we calculated a wealth score for each individual by weighting each asset by the coefficient of the first principal component [38]. Education (highest level achieved) was categorized as no formal education, primary education, secondary or high school completed, or tertiary education completed.

Statistical analysis

The statistical analysis was performed with Stata 14.1 (Stata Corp LP, College station, Texas). Descriptive analysis was conducted to characterize the study sample using weighted means (\pm standard deviations (SDs)), proportions, and unweighted *N*s. The difference in sample characteristics by the presence of multimorbidity or psychosis was tested by χ^2 tests and Student's *t*-tests (or one way ANOVA) for categorical and continuous variables, respectively. Tetrachoric correlations, which assess the relationship between each pair of physical health conditions (as multimorbidity was defined as having at least two physical health conditions), were calculated for those with subclinical psychosis or a psychosis diagnosis. Multivariable logistic regression analysis was performed to assess the association between psychosis (independent variable) and multimorbidity (dependent variable), adjusting for age, sex, education, wealth, and country. Analyses stratified by country-income level (low-income or middle-income countries) and age groups (18–44, 45–64, \geq 65 years) were also conducted. Adjustment for country was performed by including dummy variables in the models, as in previous WHS publications [32, 39]. The sample weighting and the complex study design were taken into account in the analyses. Results from the logistic regression models are presented as odds ratios (ORs) with 95% confidence intervals (CIs). The level of statistical significance was set at $P < 0.05$.

Results

Data on 242,952 individuals from 48 countries were available for the current study. Data on psychosis and

number of physical medical conditions were missing from 12.5% and 13.9%, respectively. Details on the sample characteristics are provided in Table 1. The mean (SD) age of the sample was 38.4 (16.0) years, and 50.6% were female. The prevalence of subclinical psychosis and psychosis diagnosis were 13.8% and 1.1%, respectively, while that of multimorbidity (i.e., two or more physical health conditions) was 13.2%.

Those with multimorbidity were significantly more likely to be older, of female sex, and lower socioeconomic status. The prevalence of physical health conditions is shown in Table 2. Overall, angina pectoris (14.9%), arthritis (13.2%), and chronic back pain (6.7%) were the most common conditions. For all conditions, there was a gradual increase in the prevalence from control, to subclinical psychosis, and to psychosis diagnosis. The prevalence of multimorbidity for control, subclinical psychosis, and psychosis diagnosis were 11.4%, 21.8%, and 36.0%, respectively ($P < 0.0001$). The prevalence of psychosis by the different frequencies of physical health conditions is illustrated in Fig. 1. A linear increase in the prevalence of subclinical psychosis and psychosis diagnosis with increasing number of comorbid physical health conditions was observed.

A significant positive correlation was observed for the majority of the pairs of physical health conditions among those with subclinical psychosis or psychosis diagnosis (Table 3). For those with subclinical psychosis, the strongest associations were observed for hearing problems co-occurring with visual impairment or edentulism and for arthritis co-existing with chronic back pain or angina. For those with a psychosis diagnosis, the strongest associations were observed for hearing problems co-occurring with visual impairment or edentulism, asthma co-existing with diabetes or angina or tuberculosis, and arthritis co-existing with angina. The association between psychosis and multimorbidity assessed by multivariable logistic regression is presented in Table 4. Overall, subclinical psychosis and psychosis diagnosis were associated with 2.20 (95% CI, 2.02–2.39) and 4.05 (95% CI, 3.25–5.04) times higher odds for multimorbidity. Associations in low-income and middle-income countries were similar. However, this association was stronger in the youngest age group (e.g., psychosis 18–44 years; OR = 4.68; 95% CI, 3.46–6.32) with gradual decreases in the odds being observed in the older age groups (i.e., 45–64 years and \geq 65 years).

Discussion

Physical health comorbidities are a major problem for people suffering from psychotic disorders [7, 22, 40, 41]. However, to date, multimorbidity in subclinical or clinical psychosis has received little attention. To the

Table 1 Characteristics of the sample (overall and by presence of multimorbidity)

Characteristic	Total		Multimorbidity			
			No		Yes	
	Unweighted N		Unweighted N		Unweighted N	
Psychosis category						
Control	179,429	85.1	160,143	86.8	19,286	74.1
Subclinical psychosis ^a	25,493	13.8	19,883	12.4	5,610	22.9
Psychosis diagnosis ^b	2,224	1.1	1,502	0.8	722	2.9
Sex						
Male	93,358	49.4	84,268	51.2	9,090	37.4
Female	115,846	50.6	98,964	48.8	16,882	62.6
Age, years (Mean (SD))		38.4 (16.0)		36.1 (14.5)		53.5 (16.8)
Education						
No formal	48,343	26.4	39,043	24.5	9,300	39.2
Primary	71,356	31.4	62,449	31.5	8,907	31.0
Secondary completed	72,087	32.7	66,072	34.3	6,015	22.4
Tertiary completed	17,287	9.5	15,564	9.8	1,723	7.4
Wealth (quintiles)						
Poorest	47,582	20.3	40,246	19.5	7,336	25.5
Poorer	41,449	20.0	35,989	19.7	5,460	21.9
Middle	37,705	19.8	33,350	20.0	4,355	19.0
Richer	35,378	19.9	31,597	20.3	3,781	17.2
Richest	33,305	19.9	30,111	20.5	3,194	16.3

Data are percentages unless otherwise stated

^aSubclinical psychosis refers to having at least one of delusional mood, delusions of reference and persecution, delusions of control, and hallucinations in the past 12 months but without a psychosis diagnosis

^bPsychosis diagnosis refers to self-reported lifetime diagnosis of schizophrenia/psychosis

The differences in all sample characteristics between those with and without multimorbidity were statistically significant ($P < 0.0001$)

best of our knowledge, the current study presents the first multinational community-based data investigating the association of psychosis and subclinical psychosis with physical health multimorbidity. The main findings of this study are that both subclinical psychosis and, even more so, a diagnosis of psychosis were associated with an increased odds for physical health multimorbidity. Specifically, subclinical psychosis was associated with a two-fold risk of multimorbidity and those with a diagnosis of psychosis were at a four times increased risk compared to those without any psychosis. Moreover, we observed a linear increase in the prevalence of subclinical psychosis and psychosis diagnosis with an increasing number of medical conditions, suggesting a close association between the number of diseases and psychosis/subclinical psychosis. The increased multimorbidity risk was evident in both low-income and middle-income countries. Of particular concern, the association between psychosis and multimorbidity was strongest in the younger age populations. Given that physical health multimorbidity can greatly increase the risk of mortality [15] and

healthcare costs [16], our results confirm the considerable health strain evident among the psychosis spectrum, underscoring the fact that early intervention and prevention of both psychosis and physical health morbidities are key [22, 28, 42].

Interestingly, whilst our data found that all age ranges of people with psychosis and subclinical psychosis are at increased odds of experiencing physical health multimorbidity, people aged between 18–44 were at particular risk. Antipsychotic use, smoking and sedentary lifestyle have been suggested to be the main contributors to the increased risk of cardiometabolic diseases in schizophrenia [5, 43–45]. More recently, there has been increasing concern about the poor dietary intake and, in particular, excess consumption of saturated fats, sugar, and low fiber intake, which can increase the risk of cardiometabolic disease [46]. The increased risk for diseases such as angina pectoris and diabetes observed in subclinical psychosis may also be associated with similar risk factors seen in schizophrenia since smoking and eating problems are also highly prevalent in subclinical psychosis [29, 47], although it is unlikely that

Table 2 Prevalence of physical health conditions by psychosis category

Physical health condition	Total	(a) Control	(b) Subclinical psychosis ^a	(c) Psychosis diagnosis ^b	Overall P value	P value (a) vs. (b)	P value (a) vs. (c)	P value (b) vs. (c)
Tuberculosis	1.7	1.3	3.7	7.0	<0.0001	<0.0001	<0.0001	0.0009
Visual impairment	1.3	1.2	2.0	3.8	<0.0001	<0.0001	<0.0001	<0.0001
Hearing problem	3.3	3.2	3.6	8.1	<0.0001	0.1045	<0.0001	<0.0001
Chronic back pain	6.7	5.7	11.7	15.0	<0.0001	<0.0001	<0.0001	0.0182
Edentulism	5.9	5.7	7.4	9.0	<0.0001	<0.0001	0.0011	0.1837
Arthritis	13.2	12.1	18.2	30.5	<0.0001	<0.0001	<0.0001	<0.0001
Angina pectoris	14.9	13.1	24.8	33.0	<0.0001	<0.0001	<0.0001	<0.0001
Asthma	5.1	4.5	8.5	14.8	<0.0001	<0.0001	<0.0001	<0.0001
Diabetes mellitus	3.0	2.6	5.0	6.5	<0.0001	<0.0001	<0.0001	0.0689
Number of physical health conditions								
Mean number (SD)	0.55 (0.90)	0.49 (0.86)	0.83 (0.99)	1.27 (1.33)	<0.0001	<0.0001	<0.0001	<0.0001
0	65.2	68.0	49.6	37.5	<0.0001	<0.0001	<0.0001	<0.0001
1	21.8	20.6	28.6	26.5				
2	8.6	7.5	14.1	17.8				
3	3.2	2.7	5.2	10.9				
4	1.1	0.9	1.9	5.1				
≥ 5	0.3	0.3	0.6	2.3				

Data are column percentage (i.e., the prevalence of each physical health condition among those in that psychosis category) or mean (SD). Estimates are based on weighted sample

^aSubclinical psychosis refers to having at least one of delusional mood, delusions of reference and persecution, delusions of control, and hallucinations in the past 12 months but without a psychosis diagnosis

^bPsychosis diagnosis refers to self-reported lifetime diagnosis of schizophrenia/psychosis

antipsychotics are commonly prescribed in this condition. Smoking, in particular, may increase the risk for multiple physical comorbidities in psychosis as it has also been associated with non-cardiometabolic diseases such as tuberculosis, edentulism, and asthma [48–50]. Finally, psychological distress arising from multiple physical

health conditions may also be implicated in the increased risk for subclinical psychosis [51]. The finding that the association between multimorbidity and psychosis was stronger among the younger adds further impetus to the calls for the early intervention efforts to prevent the burden of physical health comorbidity at later stages [52].




Fig. 1 Prevalence of psychosis by number of physical health conditions. Subclinical psychosis referred to having at least one of delusional mood, delusions of reference and persecution, delusions of control, and hallucinations in the past 12 months but without a psychosis diagnosis. Psychosis diagnosis refers to self-reported lifetime diagnosis of schizophrenia/psychosis

Table 3 Tetrachoric correlations of physical health conditions in subclinical psychosis and psychosis diagnosis

	Tuberculosis	Visual impairment	Hearing problem	Chronic back pain	Edentulism	Arthritis	Angina	Asthma	Diabetes
Subclinical psychosis									
Tuberculosis	1								
Visual impairment	0.0343	1							
Hearing problem	0.1030*	0.3313*	1						
Chronic back pain	0.1469*	0.2638*	0.1986*	1					
Edentulism	0.0061	0.2515*	0.3388*	0.1524*	1				
Arthritis	0.1808*	0.2033*	0.2685*	0.3180*	0.2017*	1			
Angina pectoris	0.2118*	0.1573*	0.1488*	0.2290*	0.1204*	0.3190*	1		
Asthma	0.2126*	0.1025*	0.1133*	0.1021*	0.1168*	0.1460*	0.2270*	1	
Diabetes mellitus	0.0773*	0.1850*	0.1422*	0.1224*	0.2823*	0.2222*	0.1966*	0.1709*	1
Psychosis diagnosis									
Tuberculosis	1								
Visual impairment	0.156	1							
Hearing problem	0.1201	0.3096*	1						
Chronic back pain	0.1053	0.098	0.2158*	1					
Edentulism	0.0546	0.114	0.3460*	0.0692	1				
Arthritis	0.1855*	0.2364*	0.2079*	0.2897*	0.1464*	1			
Angina pectoris	0.2844*	0.1076	0.1277*	0.1586*	0.1922*	0.3748*	1		
Asthma	0.3908*	0.1904*	0.1224	0.1290*	-0.0394	0.2360*	0.3210*	1	
Diabetes mellitus	0.2576*	0.2472*	0.1418	0.0826	0.1362	0.2136*	0.2788*	0.3674*	1

* $P < 0.05$

Across the entire sample of people from LMICs, we found evidence that better education status and wealth were both protective factors for physical multimorbidity. Literature in the general population has similarly found that wealth and higher education are protective factors for better health outcomes, including mortality and physical multimorbidity [53]. The reason for this protective relationship might be an increased awareness of health risks in higher educated people, while those with a better socioeconomic status have better health coverage or greater means to access and obtain healthcare than those with less means, in particular in LMICs [54].

This study demonstrates that physical multimorbidity is a very real problem across the psychosis spectrum in LMICs. Strategies to deal with this important issue are urgently needed, particularly targeting the earlier stage of psychotic illness. For example, relevant steps towards adequately addressing multimorbidity that have been underlined before include integrating physical multimorbidity into clinical guidelines; routinely providing self-care management strategies, including advice on a healthy and active lifestyle; prioritizing the prevention of chronic conditions; and avoiding fragmented care [22, 40, 41, 53, 55]. Existing healthcare models need to be adapted to the increasing multimorbidity rates, which will need to include

coordination with physical healthcare providers due to increasingly complex presentations. The adaptation of existing healthcare systems is especially relevant in LMICs, where all levels of care must be carefully planned in the context of economic restraints. The Innovative Care for Chronic Conditions framework developed by WHO provides an initial roadmap to cope with chronic conditions in developing countries, but there still is a need to fully incorporate physical multimorbidity within primary and mental healthcare settings [56]. First of all, there is a clear need to increase awareness of the importance of physical health needs of people with psychosis among primary and mental healthcare providers in LMICs. Continued medical education (a common practice in LMICs [57]) should be used to inform health providers about the importance of assessing physical health risks in people with psychosis. Health providers in LMICs need to be informed that their roles extend beyond taking care of the mental health of their patients and assume responsibility for both the mental and physical health of their patients [57]. There is also the need for mental health education institutions that train medical personnel to include physical health screening/monitoring as part of their curriculum. Policymakers should be made aware that investment in continued medical education and in the

Table 4 Association between psychosis and multimorbidity (outcome) estimated by multivariable logistic regression analysis

Characteristic	Total		Low-income countries		Middle-income countries		Age 18–44 years		Age 45–64 years		Age ≥ 65 years	
	OR	95% CI	OR	95% CI	OR	95% CI	OR	95% CI	OR	95% CI	OR	95% CI
Psychosis category												
Control	1.00		1.00		1.00		1.00		1.00		1.00	
Subclinical psychosis ^a	2.20***	(2.02–2.39)	2.03***	(1.80–2.28)	2.43***	(2.16–2.74)	2.71***	(2.40–3.05)	1.93***	(1.68–2.20)	1.69***	(1.40–2.04)
Psychosis diagnosis ^b	4.05***	(3.25–5.04)	3.99***	(3.00–5.31)	4.07***	(2.93–5.65)	4.68***	(3.46–6.32)	3.78***	(2.77–5.16)	2.22**	(1.34–3.68)
Sex												
Male	1.00		1.00		1.00		1.00		1.00		1.00	
Female	1.66***	(1.56–1.77)	1.59***	(1.45–1.74)	1.74***	(1.59–1.89)	1.70***	(1.55–1.88)	1.77***	(1.60–1.96)	1.39***	(1.21–1.59)
Age, years	1.07***	(1.06–1.07)	1.06***	(1.06–1.06)	1.07***	(1.07–1.08)	1.07***	(1.06–1.07)	1.07***	(1.06–1.08)	1.06***	(1.05–1.07)
Education												
No formal	1.00		1.00		1.00		1.00		1.00		1.00	
Primary	0.97	(0.88–1.07)	0.99	(0.88–1.12)	0.85*	(0.74–0.99)	0.98	(0.85–1.13)	0.95	(0.82–1.11)	0.81*	(0.67–0.99)
Secondary completed	0.72***	(0.64–0.82)	0.71***	(0.60–0.85)	0.68***	(0.57–0.82)	0.74***	(0.62–0.88)	0.64***	(0.52–0.79)	0.76*	(0.58–0.99)
Tertiary completed	0.61***	(0.51–0.74)	0.54**	(0.35–0.83)	0.61***	(0.50–0.74)	0.62*	(0.43–0.90)	0.59***	(0.46–0.75)	0.66*	(0.48–0.91)
Wealth (quintiles)												
Poorest	1.00		1.00		1.00		1.00		1.00		1.00	
Poorer	0.92	(0.83–1.01)	0.94	(0.81–1.07)	0.90	(0.80–1.02)	0.91	(0.79–1.05)	0.97	(0.84–1.12)	0.82*	(0.68–1.00)
Middle	0.83***	(0.76–0.92)	0.82**	(0.71–0.93)	0.87*	(0.76–0.99)	0.79**	(0.69–0.91)	0.86*	(0.73–1.00)	0.92	(0.75–1.13)
Richer	0.84***	(0.76–0.92)	0.85*	(0.74–0.98)	0.84**	(0.74–0.96)	0.80**	(0.69–0.92)	0.90	(0.78–1.05)	0.89	(0.72–1.09)
Richest	0.85**	(0.76–0.96)	0.90	(0.77–1.05)	0.83*	(0.70–0.98)	0.79*	(0.67–0.95)	0.97	(0.81–1.15)	0.88	(0.69–1.12)

OR odds ratio, CI confidence interval

Models are adjusted for all covariates in the respective columns and country

^aSubclinical psychosis refers to having at least one of delusional mood, delusions of reference and persecution, delusions of control, and hallucinations in the past 12 months but without a psychosis diagnosis

^bPsychosis diagnosis refers to self-reported lifetime diagnosis of schizophrenia/psychosis

* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$

screening for physical health risks is likely to optimize mental and physical health outcomes. However, effective monitoring of metabolic risks is not sufficient on its own, as appropriate treatment is also mandatory [5, 58]. Finally, evidence indicates that the treatment of somatic diseases is often neglected in populations with psychotic disorders compared to non-psychotic healthcare users [40, 41]. For example, routine medical appointments are scheduled less often and medications for cardio-metabolic conditions [59–63] are sub-optimally prescribed when patients with psychosis are compared to those who are non-psychotic.

Limitations

The current findings should be interpreted in light of some study limitations. First, the study was cross-sectional, therefore cause and effect cannot be deduced with certainty. Nonetheless, regardless of directionality, this survey provides a clear public health message. In addition, the diagnosis of psychosis was not assessed by a clinical interview. Moreover, the self-report measure may have led to a bias in the diagnosis of the medical conditions, particularly in older subjects. However, this potential bias would have been the same across all three compared groups, so that the observed gradient remains meaningful. In addition, the dataset only covered nine major physical comorbidities. Therefore, other physical health comorbidities may well have been evident but not identified in the dataset. Future research should consider additional cardiometabolic conditions, such as hypertension and stroke, which were missing from the evaluated questionnaires. Furthermore, although multimorbidity, defined by two or more physical conditions, has a relevant impact on morbidity, functioning, quality of life, and mortality [12–16], we recognize that specific physical illnesses are different regarding their severity and impact on these outcomes. In addition, due to poor/incomplete data, we were not able to investigate the impact of smoking, substance use, and medication on the relationship between psychosis and multimorbidity. Future research should attempt to assess the degree to which these factors contribute to this relationship. Next, future research should seek to explore the relationship between psychosis and multimorbidity in high-income countries as there may be contextual differences compared with LMICs. For example, as has been reported previously [32], our LMIC sample had a higher prevalence of subclinical psychosis than generally reported figures from high-income countries. Moreover, the sample is based on community dwelling people, whereas other groups of people with psychosis (e.g., in-patients) may have poorer physical health; the study does not account for this at-risk group. Finally, the

reliance on self-report and not medical records may mean that our data are actually underestimates. Despite these limitations, the strengths of the study include a large sample size and the multi-national scope, including most regions of the world, but in particular understudied LMICs in Africa, Latin-America, Asia, and Eastern Europe.

Conclusions

In conclusion, people with psychosis and subclinical psychosis in LMICs had a higher risk for multiple physical conditions. Given that levels of stigma attached to mental disorders may be high in this setting [64], and treatment for both mental disorders and physical health conditions are often suboptimal in LMICs, physical multimorbidity may be associated with a particularly devastating consequence for those with psychosis in this setting. Future studies are needed to assess the impact and cost-effectiveness of global preventive and therapeutic strategies targeting physical multimorbidity in individuals across the full psychotic spectrum.

Abbreviations

CI: confidence intervals; LMIC: low- and middle-income countries; OR: odds ratios; SD: standard deviations; WHO: World Health Organization; WHS: World Health Survey

Acknowledgements

BS and FG receive funding from the National Institute for Health Research Collaboration for Leadership in Applied Health Research & Care Funding scheme. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research, or the Department of Health. AK's work was supported by the Miguel Servet contract financed by the CP13/00150 and PI15/00862 projects, integrated into the National R + D + I and funded by the ISCIII – General Branch Evaluation and Promotion of Health Research – and the European Regional Development Fund (ERDF-FEDER). DV is funded by the Research Foundation – Flanders (FWO – Vlaanderen).

Availability of data and materials

The database used for the current study is publicly available (upon registration) from <http://www.who.int/healthinfo/survey/en/>.

Authors' contribution

BS, AK, and DV designed the study. AK led the data analysis with support from BS. BS, DV, AK, and CUC wrote the manuscript. All authors provided critical comments on the manuscript and approved the final version.

Competing interests

CUC has been a consultant and/or advisor to or has received honoraria from Alkermes, Forum, Gerson Lehrman Group, IntraCellular Therapies, Janssen/J&J, Lundbeck, Medavante, Medscape, Otsuka, Pfizer, ProPhase, Sunovion, Supernus, Takeda, and Teva. He has provided expert testimony for Bristol-Myers Squibb, Janssen, and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck and Pfizer. He received grant support from Takeda. FG has received honoraria for advisory work and lectures from Roche, BMS, Lundbeck, Otsuka, and Sunovion, is participating in a research project funded by NHS Innovations & Janssen, and has a family member with professional links and share options with Lilly and GSK; BS, AK, NV, DV, MS, JL, and AJM have nothing to declare.

Ethics approval and consent to participate

Ethical approval was obtained from each of the following committees in the respective countries for the World Health Survey:

Country	Ethical committee approving the study
Bangladesh	Mitra and Associates
Bosnia Herzegovina	The Federal Public Health Institute
Brazil	Fundacao Oswaldo Cruz
Burkina Faso	Institut de Recherche en Sciences de la Santé
Chad	Faculté des Sciences de la Santé, Univ N'Djamena
China	Centre for Health Statistics Information
Comoros	Bureau Comorien de Conseil
Congo	Unité de recherche sur les systèmes de santé
Ivory Coast	Ministère de la Santé
Croatia	The Croatian National Institute of Public Health
Czech Republic	Institute of Health Information and Statistics
Dominican Republic	Centro de Estudios Sociales y Demográficos (CESDEM)
Ecuador	Fundación Ecuatoriana para la Salud y el Desarrollo (FESALUD)
Estonia	Saar Poll Ltd.
Ethiopia	Department of Community Health, Jimma University
Georgia	Georgian State Medical Academy (GSMA)
Ghana	Department of Community Health, Ghana Medical School
Hungary	Johan Bela National Centre for Epidemiology
India	International Institute of Population Sciences
Kazakhstan	Kazakstan School of Public Health (KSPH)
Kenya	Central Bureau of Statistics
Laos	National Institute of Public Health, Ministry of Health
Latvia	The Health Promotion Center
Malawi	Centre for Social Research (CSR)
Malaysia	Public Health Institute, Ministry of Health
Mali	Cellule de Planification et de Statistique (CPS)
Mauritania	Office Nationale de la Statistique (ONS)
Mauritius	Mauritius Institute of Health
Mexico	Instituto Nacional de Salud Pública
Morocco	Ministère de la Santé
Myanmar	Department of Medical Research, Ministry of Health
Namibia	Ministry of Health
Nepal	ORG-MARG Nepal PVT, Ltd.
Pakistan	Ministry of Health
Paraguay	Fac. de Ciencias Veterinarias, Univ. Nacional/DGEEC
Philippines	College of Medicine, University of the Philippines
Russia	Semashko Institute for Research on Social Hygiene
Senegal	Direction Etudes, Recherche et Formation (DERF)
Slovakia	Environment, s.c., Centre of Biostatistics and Environment
South Africa	Community Agency for Social Enquiry (CASE)
Sri Lanka	Ministry of Health
Swaziland	Faculty of Health Sciences, Univ. of Swaziland
Tunisia	Institut National de la Santé Publique
Ukraine	Odessa State Medical University
Uruguay	Centro de Estudios de Economía y Salud (CEES)
Vietnam	Ministry of Health
Zambia	School of Humanities & Social Sciences, University of Zambia
Zimbabwe	Community Health, University of Zimbabwe

Author details

¹Physiotherapy Department, South London and Maudsley NHS Foundation Trust, Denmark Hill, London SE5 8AZ, UK. ²Health Service and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, De Crespigny Park, London, Box SE5 8AF, UK. ³Research and Development Unit, Parc Sanitari Sant Joan de Déu, Universitat de Barcelona, Fundació Sant Joan de Déu, Dr. Antoni Pujadas, 42, Sant Boi de Llobregat, Barcelona 08830, Spain. ⁴Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Monforte de Lemos 3-5 Pabellón 11, Madrid 28029, Spain. ⁵Geriatrics Division, Department of Medicine-DIMED, University of Padova, Padova, Italy. ⁶Institute of Clinical Research and Education in Medicine (IREM), Padova, Italy. ⁷KU Leuven Department of Rehabilitation Sciences, Leuven, Belgium. ⁸KU Leuven, University Psychiatric Center KU Leuven, Leuven-Kortenberg, Belgium. ⁹Department of Neurosciences, University of Padova, Padova, Italy. ¹⁰Local Health Unit ULSS 17, Mental Health Department, Monselice, Padova, Italy. ¹¹Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience King's College London, London, UK. ¹²Department of Psychiatry and Translational Psychiatry Research Group, Faculty of Medicine, Federal University of Ceará, Fortaleza, CE, Brazil. ¹³Department of Psychiatry, Royal College of Surgeons in Ireland, Dublin, Ireland. ¹⁴Department of Cancer and Molecular Medicine, University of Leicester, Leicester, UK. ¹⁵Kyambogo University, Kampala, Uganda. ¹⁶Butabika National Referral and Mental Health Hospital, Kampala, Uganda. ¹⁷The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, New York, USA. ¹⁸Hofstra Northwell School of Medicine, Hempstead, New York, USA.

Received: 24 July 2016 Accepted: 26 October 2016

Published online: 22 November 2016

References

- Lawrence D, Hancock KJ, Kisely S. The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers. *BMJ*. 2013;346:f2539.
- Walker ER, McGee RE, Druss BG. Mortality in Mental Disorders and Global Disease Burden Implications: A Systematic Review and Meta-analysis. *JAMA Psychiatry*. 2015;72(4):334–41.
- Chang CK, Hayes RD, Broadbent M, Fernandes AC, Lee W, Hotopf M, et al. All-cause mortality among people with serious mental illness (SMI), substance use disorders, and depressive disorders in southeast London: a cohort study. *BMC Psychiatry*. 2010;10:77.
- Gardner-Sood P, Lally J, Smith S, Atakan Z, Ismail K, Greenwood KE, et al. Cardiovascular risk factors and metabolic syndrome in people with established psychotic illnesses: baseline data from the IMPACT randomized controlled trial. *Psychol Med*. 2015;45(12):2619–29.
- Vancampfort D, Stubbs B, Mitchell AJ, De Hert M, Wampers M, Ward PB, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. *World Psychiatry*. 2015;14(3):339–47.
- Vancampfort D, Correll CU, Galling B, Probst M, De Hert M, Ward PB, et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. *World Psychiatry*. 2016;15(2):166–74.
- Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. *World Psychiatry*. 2015;14(2):119–36.
- Foley DL, Mackinnon A, Watts GF, Shaw JE, Magliano DJ, Castle DJ, et al. Cardiometabolic risk indicators that distinguish adults with psychosis from the general population, by age and gender. *PLoS One*. 2013;8(12):e82606.
- Foley DL, Mackinnon A, Morgan VA, Watts GF, McGrath JJ, Castle DJ, et al. Predictors of type 2 diabetes in a nationally representative sample of adults with psychosis. *World Psychiatry*. 2014;13(2):176–83.
- Stubbs B, Mitchell AJ, De Hert M, Correll CU, Soundy A, Stroobants M, et al. The prevalence and moderators of clinical pain in people with schizophrenia: a systematic review and large scale meta-analysis. *Schizophr Res*. 2014;160(1–3):1–8.
- Stubbs B, Gardner-Sood P, Smith S, Ismail K, Greenwood K, Patel A, et al. Pain is independently associated with reduced health related quality of life in people with psychosis. *Psychiatry Res*. 2015;230(2):585–91.

12. Ryan A, Wallace E, O'Hara P, Smith SM. Multimorbidity and functional decline in community-dwelling adults: a systematic review. *Health Qual Life Outcomes*. 2015;13:168.
13. Fortin M, Lapointe L, Hudon C, Vanasse A, Ntetu AL, Maltais D. Multimorbidity and quality of life in primary care: a systematic review. *Health Qual Life Outcomes*. 2004;2:51.
14. Gallo JJ, Hwang S, Joo JH, Bogner HR, Morales KH, Bruce ML, et al. Multimorbidity, depression, and mortality in primary care: randomized clinical trial of an evidence-based depression care management program on mortality risk. *J Gen Intern Med*. 2016;31(4):380–6.
15. Di Angelantonio E, Kaptoge S, Wormser D, Willeit P, Butterworth AS, Bansal N, et al. Association of cardiometabolic multimorbidity with mortality. *JAMA*. 2015;314(1):52–60.
16. Lehnert T, Heider D, Leicht H, Heinrich S, Corrieri S, Luppia M, et al. Review: health care utilization and costs of elderly persons with multiple chronic conditions. *Med Care Res Rev*. 2011;68(4):387–420.
17. Smith DJ, Langan J, McLean G, Guthrie B, Mercer SW. Schizophrenia is associated with excess multiple physical-health comorbidities but low levels of recorded cardiovascular disease in primary care: cross-sectional study. *BMJ Open*. 2013;3(4): pii: e002808.
18. Moreno C, Nuevo R, Chatterji S, Verdes E, Arango C, Ayuso-Mateos JL. Psychotic symptoms are associated with physical health problems independently of a mental disorder diagnosis: results from the WHO World Health Survey. *World Psychiatry*. 2013;12(3):251–7.
19. Saha S, Scott J, Varghese D, McGrath J. The association between physical health and delusional-like experiences: a general population study. *PLoS One*. 2011;6(4), e18566.
20. Koyanagi A, Stickley A, Haro JM. Subclinical psychosis and pain in an English national sample: The role of common mental disorders. *Schizophr Res*. 2016;175(1–3):209–15.
21. Sharifi V, Eaton WW, Wu LT, Roth KB, Burchett BM, Mojtabai R. Psychotic experiences and risk of death in the general population: 24–27 year follow-up of the Epidemiologic Catchment Area study. *Br J Psychiatry*. 2015;207(1):30–6.
22. Docherty M, Stubbs B, Gaughran F. Strategies to deal with comorbid physical illness in psychosis. *Epidemiol Psychiatr Sci*. 2016;25(3):197–204.
23. Moore S, Shiers D, Daly B, Mitchell AJ, Gaughran F. Promoting physical health for people with schizophrenia by reducing disparities in medical and dental care. *Acta Psychiatr Scand*. 2015;132(2):109–21.
24. Garin N, Koyanagi A, Chatterji S, Tyrovolas S, Olaya B, Leonardi M, et al. Global multimorbidity patterns: a cross-sectional, population-based, multi-country study. *J Gerontol A Biol Sci Med Sci*. 2016;71(2):205–14.
25. Rukat A, Musisi S, Strohle A, Mundt AP. Prescription patterns of psychotropic medications for the treatment of psychotic disorders in the largest mental health institutions of Uganda. *J Clin Psychopharmacol*. 2014;34(5):571–6.
26. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. *Lancet*. 2013; 382(9896):951–62.
27. Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. *Neuropsychopharmacology*. 2010;35(9):1997–2004.
28. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. *Nat Rev Endocrinol*. 2012;8(2):114–26.
29. Koyanagi A, Stickley A, Haro JM. Psychotic symptoms and smoking in 44 countries. *Acta Psychiatr Scand*. 2016;133(6):497–505.
30. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. *Lancet*. 2007;370(9590):851–8.
31. Ustun TB, Chatterji S, Mechbal A, Murray CJL, WHS Collaborating Groups. The World Health Surveys. In: Murray CJL, Evans DB, editors. *Health systems performance assessment: debates, methods and empiricism*. Geneva: World Health Organization; 2003. p. 797–808.
32. Nuevo R, Chatterji S, Verdes E, Naidoo N, Arango C, Ayuso-Mateos JL. The continuum of psychotic symptoms in the general population: a cross-national study. *Schizophr Bull*. 2012;38(3):475–85.
33. Rose GA. The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. *Bull World Health Organ*. 1962;27:645–58.
34. Freeman EE, Roy-Gagnon MH, Samson E, Haddad S, Aubin MJ, Vela C, et al. The global burden of visual difficulty in low, middle, and high income countries. *PLoS One*. 2013;8(5), e63315.
35. Goldhaber-Fiebert JD, Jeon CY, Cohen T, Murray MB. Diabetes mellitus and tuberculosis in countries with high tuberculosis burdens: individual risks and social determinants. *Int J Epidemiol*. 2011;40(2):417–28.
36. Kessler RC, Ustun TB. The World Mental Health (WMH) Survey Initiative Version of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI). *Int J Methods Psychiatr Res*. 2004;13(2):93–121.
37. Cooper L, Peters L, Andrews G. Validity of the Composite International Diagnostic Interview (CIDI) psychosis module in a psychiatric setting. *J Psychiatr Res*. 1998;32(6):361–8.
38. Akinyemiju TF. Socio-economic and health access determinants of breast and cervical cancer screening in low-income countries: analysis of the World Health Survey. *PLoS One*. 2012;7(11), e48834.
39. Koyanagi A, Oh H, Stickley A, Haro JM, DeVylder J. Risk and functional significance of psychotic experiences among individuals with depression in 44 low- and middle-income countries. *Psychol Med*. 2016;46(12):2655–65.
40. De Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. *World Psychiatry*. 2011;10(1):52–77.
41. De Hert M, Cohen D, Bobes J, Cetkovich-Bakmas M, Leucht S, Ndeti DM, et al. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. *World Psychiatry*. 2011;10(2):138–51.
42. Correll CU, Hauser M, Auther AM, Cornblatt BA. Research in people with psychosis risk syndrome: a review of the current evidence and future directions. *J Child Psychol Psychiatry*. 2010;51(4):390–431.
43. Vancampfort D, Mitchell AJ, Hert M, Sienaert P, Probst M, Buys R, et al. Type 2 diabetes in patients with major depressive disorder: a meta-analysis of prevalence estimates and predictors. *Depress Anxiety*. 2015;32(10):763–73.
44. Stubbs B, Vancampfort D, Bobes J, De Hert M, Mitchell AJ. How can we promote smoking cessation in people with schizophrenia in practice? A clinical overview. *Acta Psychiatr Scand*. 2015;132(2):122–30.
45. Kouidrat Y, Amad A, Lalau JD, Loas G. Eating disorders in schizophrenia: implications for research and management. *Schizophr Res Treatment*. 2014;2014:791573.
46. Dipasquale S, Pariante CM, Dazzan P, Aguglia E, McGuire P, Mondelli V. The dietary pattern of patients with schizophrenia: A systematic review. *J Psychiatr Res*. 2013;47(2):197–207.
47. Koyanagi A, Stickley A, Haro JM. Psychotic-like experiences and disordered eating in the English general population. *Psychiatry Res*. 2016;241:26–34.
48. Felton DA. Edentulism and comorbid factors. *J Prosthodont*. 2009;18(2):88–96.
49. Hassmiller KM. The association between smoking and tuberculosis. *Salud Publica Mex*. 2006;48 Suppl 1:S201–16.
50. Silvestri M, Franchi S, Pistorio A, Petecchia L, Rusconi F. Smoke exposure, wheezing, and asthma development: a systematic review and meta-analysis in unselected birth cohorts. *Pediatr Pulmonol*. 2015;50(4):353–62.
51. Saha S, Scott JG, Varghese D, McGrath J. The association between general psychological distress and delusional-like experiences: a large population-based study. *Schizophr Res*. 2011;127(1–3):246–51.
52. Samaras K, Correll CU, Curtis J. Premature mortality and schizophrenia – the need to heal right from the start. *JAMA Psychiat*. 2016;73(5):535–6.
53. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. *Lancet*. 2012;380(9836):37–43.
54. Asante A, Price J, Hayden A, Jan S, Wiseman V. Equity in health care financing in low- and middle-income countries: a systematic review of evidence from studies using benefit and financing incidence analyses. *PLoS One*. 2016;11(4), e0152866.
55. Kadam U. Redesigning the general practice consultation to improve care for patients with multimorbidity. *BMJ*. 2012;345, e6202.
56. Oni T, McGrath N, BeLue R, Roderick P, Colagiuri S, May CR, et al. Chronic diseases and multi-morbidity—a conceptual modification to the WHO ICCM model for countries in health transition. *BMC Public Health*. 2014;14:575.
57. Mugisha J, Ssebunnya J, Kigozi FN. Towards understanding governance issues in integration of mental health into primary health care in Uganda. *Int J Ment Health Syst*. 2016;10:25.
58. Mitchell AJ, De Hert M. Promotion of physical health in persons with schizophrenia: can we prevent cardiometabolic problems before they begin? *Acta Psychiatr Scand*. 2015;132(2):83–5.
59. Mitchell AJ, Malone D, Doebbeling CC. Quality of medical care for people with and without comorbid mental illness and substance misuse: systematic review of comparative studies. *Br J Psychiatry*. 2009;194(6):491–9.

60. Mitchell AJ, Lord O. Do deficits in cardiac care influence high mortality rates in schizophrenia? A systematic review and pooled analysis. *J Psychopharmacol*. 2010;24(4 Suppl):69–80.
61. Mitchell AJ, Lawrence D. Revascularisation and mortality rates following acute coronary syndromes in people with severe mental illness: comparative meta-analysis. *Br J Psychiatry*. 2011;198(6):434–41.
62. Mitchell AJ, Lord O, Malone D. Differences in the prescribing of medication for physical disorders in individuals with v. without mental illness: meta-analysis. *Br J Psychiatry*. 2012;201(6):435–43.
63. Mitchell AJ, Pereira IES, Yadegarfar M, Pepereke S, Mugadza V, Stubbs B. Breast cancer screening in women with mental illness: comparative meta-analysis of mammography uptake. *Br J Psychiatry*. 2014;205(6):428–35.
64. Alonso J, Buron A, Bruffaerts R, He Y, Posada-Villa J, Lepine JP, et al. Association of perceived stigma and mood and anxiety disorders: results from the World Mental Health Surveys. *Acta Psychiatr Scand*. 2008;118(4):305–14.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

